Skip to main content

Table 4 Single-nucleotide polymorphisms associated with serum prolactin levels in the Polish Breast Cancer Studya

From: Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland

Single-nucleotide polymorphism Number Geometric meanb 95% CI Ptrend
Premenopausal controls     
   PRLR     
rs62355518     
AA 140 11.16 8.81-14.15 0.01
AG 55 8.90 6.87-11.51  
GG 5 10.61 6.60-17.05  
rs10941235     
GG 101 11.05 8.66-14.08 0.01
AG 90 9.24 7.21-11.85  
AA 12 9.37 6.57-13.37  
rs1610218     
GG 192 10.47 8.26-13.28 0.01
AG 13 6.95 4.81-10.03  
AA 0    
rs34024951     
GG 170 10.25 8.07-13.02 0.02
AG 34 8.38 6.27-11.19  
AA 1 6.60 2.53-17.21  
rs9292575     
CC 162 10.07 7.97-12.71 0.03
AC 39 13.38 10.10-17.72  
AA 3 7.32 4.19-12.80  
Postmenopausal controls     
   PRL     
rs849872     
AA 300 7.63 6.23-9.35 0.01
AG 126 8.34 6.76-10.28  
GG 13 9.69 7.10-13.24  
  1. aA complete list of single-nucleotide polymorphism associations with serum prolactin concentrations can be found in Supplementary tables S3a and S3b in Additional file 1. bAdjusted for age, study site, time of blood collection, and time since last period (premenopausal only). CI, confidence interval; PRL, prolactin (gene); PRLR, prolactin receptor (gene).